Medical News

---

• Blood biomarkers predict suicidality
• Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC
• Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC
• Blood biomarkers predict suicidality
• Heritability of severe mental illness may be underestimated
• Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC
• Heritability of severe mental illness may be underestimated
• Findings support partial nephrectomy for T1b RCC
• Time to RCC recurrence prognostic threshold challenged
• Muscle density improves mRCC prognosis prediction
• Tumor vessel density linked to mRCC treatment response
• Testosterone improves exercise capacity in men with COPD

Blood biomarkers predict suicidality Posted: 28 Aug 2013 05:00 PM PDT Researchers have found possible blood biomarkers for suicidal behavior that could help identify psychiatric patients at risk.

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC Posted: 28 Aug 2013 05:00 PM PDT Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC Posted: 28 Aug 2013 05:00 PM PDT Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

Blood biomarkers predict suicidality Posted: 28 Aug 2013 05:00 PM PDT Researchers have found possible blood biomarkers for suicidal behavior that could help identify psychiatric patients at risk.

Heritability of severe mental illness may be underestimated Posted: 28 Aug 2013 05:00 PM PDT Around one in three children of parents with a severe mental illness – schizophrenia, bipolar disorder, or major depressive disorder – will develop such a disorder themselves by early adulthood, a meta-analysis has found.

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC Posted: 28 Aug 2013 05:00 PM PDT Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

Heritability of severe mental illness may be underestimated Posted: 28 Aug 2013 05:00 PM PDT Around one in three children of parents with a severe mental illness – schizophrenia, bipolar disorder, or major depressive disorder – will develop such a disorder themselves by early adulthood, a meta-analysis has found.

Findings support partial nephrectomy for T1b RCC Posted: 27 Aug 2013 05:00 PM PDT Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.

Time to RCC recurrence prognostic threshold challenged Posted: 27 Aug 2013 05:00 PM PDT A large study confirms the prognostic value of time to recurrence after surgery for renal cell carcinoma, and also suggests the need to reduce the threshold for early recurrence.

Muscle density improves mRCC prognosis prediction Posted: 27 Aug 2013 05:00 PM PDT Patients with metastatic renal cell carcinoma treated with targeted therapies have a better prognosis if they also have a high quality of muscle, study findings indicate.

Tumor vessel density linked to mRCC treatment response Posted: 27 Aug 2013 05:00 PM PDT Changes in tumor vessel density correlate with response and resistance to anti-angiogenic therapy in patients with metastatic renal cell carcinoma, study findings suggest.

Testosterone improves exercise capacity in men with COPD Posted: 27 Aug 2013 05:00 PM PDT A systematic review and meta-analysis confirms that testosterone therapy improves exercise capacity in men with chronic obstructive pulmonary disease.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610